FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma
Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGB...
Gespeichert in:
| Veröffentlicht in: | Disease markers 2020, Vol.2020 (2020), p.1-7 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | 2020 |
| container_start_page | 1 |
| container_title | Disease markers |
| container_volume | 2020 |
| creator | Zhao, Jizong Lin, Fa Zeng, Chaofan Ge, Peicong Zhang, Qian Li, Junsheng Wang, Wen |
| description | Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. Methods. We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. Results. We found that FAM225B was upregulated in rGBMs (P=0.0009). The expression of FAM225B increased with the grades of gliomas (P |
| doi_str_mv | 10.1155/2020/8888085 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7704151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2467505207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-8d1b94daaa502b998eb4d5403a69b90e5ca37e282e3faa03d7f890731ad425cc3</originalsourceid><addsrcrecordid>eNqNkt1rFDEUxYModl1981kGfBF02puvTfIirMVuC1VL0edwJ5PppsxO2mTG4n9vlt1W7ZP3JVzy4-QcTgh5TeGQUimPGDA40mVAyydkRrWStV5weEpmwJSugQk4IC9yvgagzAjznBxwzoyRQGdkdbL8wpj8VJ3lCquLFK-GmMfgqn5wl1-XVRdTdYFj8MOYq7swrqtL76aUyl6t-hCbHvMYN_iSPOuwz_7V_pyTHyefvx-f1uffVmfHy_PaCUXHWre0MaJFRAmsMUb7RrRSAMeFaQx46ZArzzTzvEME3qpOG1CcYiuYdI7Pyced7s3UbHzrio-Evb1JYYPpl40Y7L83Q1jbq_jTKgWCSloE3u0FUrydfB7tJmTn-x4HH6dsmVgYKG9SKOjbR-h1nNJQ4m0pJUGyYm1OPuwol2LOyXcPZijYbUN225DdN1TwN38HeIDvKynA-x2wDkOLd-E_5XxhfId_aCoFLf_gNxM0oPs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2467505207</pqid></control><display><type>article</type><title>FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhao, Jizong ; Lin, Fa ; Zeng, Chaofan ; Ge, Peicong ; Zhang, Qian ; Li, Junsheng ; Wang, Wen</creator><contributor>Tu, Wen-Jun ; Wen-Jun Tu</contributor><creatorcontrib>Zhao, Jizong ; Lin, Fa ; Zeng, Chaofan ; Ge, Peicong ; Zhang, Qian ; Li, Junsheng ; Wang, Wen ; Tu, Wen-Jun ; Wen-Jun Tu</creatorcontrib><description>Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. Methods. We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. Results. We found that FAM225B was upregulated in rGBMs (P=0.0009). The expression of FAM225B increased with the grades of gliomas (P<0.0001). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group (P=0.0041). Similar result was found in the training set (P=0.0340) and verified in the validation set (P=0.0292). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs (P=0.003). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. Conclusions. FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs.</description><identifier>ISSN: 0278-0240</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2020/8888085</identifier><identifier>PMID: 33299501</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Biological activity ; Biomarkers ; Biomarkers, Tumor - genetics ; Brain Neoplasms - genetics ; Brain Neoplasms - mortality ; Brain Neoplasms - pathology ; Cell adhesion & migration ; Cell cycle ; Cell division ; Cell migration ; Chemotherapy ; Datasets ; Female ; Gene Expression Regulation, Neoplastic ; Gene regulation ; Gene Regulatory Networks ; Gene sequencing ; Genomes ; Glioblastoma ; Glioblastoma - genetics ; Glioblastoma - mortality ; Glioblastoma - pathology ; Glioma ; Humans ; Male ; Medical prognosis ; Multivariate analysis ; Neoplasm Grading ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Patients ; Prognosis ; Radiation therapy ; Regression Analysis ; Ribonucleic acid ; RNA ; RNA, Long Noncoding - genetics ; Software ; Survival ; Survival Analysis ; Training ; Transcription ; Tumors ; Up-Regulation</subject><ispartof>Disease markers, 2020, Vol.2020 (2020), p.1-7</ispartof><rights>Copyright © 2020 Junsheng Li et al.</rights><rights>Copyright © 2020 Junsheng Li et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Junsheng Li et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-8d1b94daaa502b998eb4d5403a69b90e5ca37e282e3faa03d7f890731ad425cc3</citedby><cites>FETCH-LOGICAL-c471t-8d1b94daaa502b998eb4d5403a69b90e5ca37e282e3faa03d7f890731ad425cc3</cites><orcidid>0000-0001-7304-0255 ; 0000-0002-6735-460X ; 0000-0001-5099-9834 ; 0000-0002-4047-0256</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704151/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704151/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33299501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Tu, Wen-Jun</contributor><contributor>Wen-Jun Tu</contributor><creatorcontrib>Zhao, Jizong</creatorcontrib><creatorcontrib>Lin, Fa</creatorcontrib><creatorcontrib>Zeng, Chaofan</creatorcontrib><creatorcontrib>Ge, Peicong</creatorcontrib><creatorcontrib>Zhang, Qian</creatorcontrib><creatorcontrib>Li, Junsheng</creatorcontrib><creatorcontrib>Wang, Wen</creatorcontrib><title>FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. Methods. We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. Results. We found that FAM225B was upregulated in rGBMs (P=0.0009). The expression of FAM225B increased with the grades of gliomas (P<0.0001). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group (P=0.0041). Similar result was found in the training set (P=0.0340) and verified in the validation set (P=0.0292). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs (P=0.003). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. Conclusions. FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs.</description><subject>Biological activity</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - pathology</subject><subject>Cell adhesion & migration</subject><subject>Cell cycle</subject><subject>Cell division</subject><subject>Cell migration</subject><subject>Chemotherapy</subject><subject>Datasets</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene regulation</subject><subject>Gene Regulatory Networks</subject><subject>Gene sequencing</subject><subject>Genomes</subject><subject>Glioblastoma</subject><subject>Glioblastoma - genetics</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - pathology</subject><subject>Glioma</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Multivariate analysis</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Regression Analysis</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Long Noncoding - genetics</subject><subject>Software</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Training</subject><subject>Transcription</subject><subject>Tumors</subject><subject>Up-Regulation</subject><issn>0278-0240</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNqNkt1rFDEUxYModl1981kGfBF02puvTfIirMVuC1VL0edwJ5PppsxO2mTG4n9vlt1W7ZP3JVzy4-QcTgh5TeGQUimPGDA40mVAyydkRrWStV5weEpmwJSugQk4IC9yvgagzAjznBxwzoyRQGdkdbL8wpj8VJ3lCquLFK-GmMfgqn5wl1-XVRdTdYFj8MOYq7swrqtL76aUyl6t-hCbHvMYN_iSPOuwz_7V_pyTHyefvx-f1uffVmfHy_PaCUXHWre0MaJFRAmsMUb7RrRSAMeFaQx46ZArzzTzvEME3qpOG1CcYiuYdI7Pyced7s3UbHzrio-Evb1JYYPpl40Y7L83Q1jbq_jTKgWCSloE3u0FUrydfB7tJmTn-x4HH6dsmVgYKG9SKOjbR-h1nNJQ4m0pJUGyYm1OPuwol2LOyXcPZijYbUN225DdN1TwN38HeIDvKynA-x2wDkOLd-E_5XxhfId_aCoFLf_gNxM0oPs</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Zhao, Jizong</creator><creator>Lin, Fa</creator><creator>Zeng, Chaofan</creator><creator>Ge, Peicong</creator><creator>Zhang, Qian</creator><creator>Li, Junsheng</creator><creator>Wang, Wen</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7304-0255</orcidid><orcidid>https://orcid.org/0000-0002-6735-460X</orcidid><orcidid>https://orcid.org/0000-0001-5099-9834</orcidid><orcidid>https://orcid.org/0000-0002-4047-0256</orcidid></search><sort><creationdate>2020</creationdate><title>FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma</title><author>Zhao, Jizong ; Lin, Fa ; Zeng, Chaofan ; Ge, Peicong ; Zhang, Qian ; Li, Junsheng ; Wang, Wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-8d1b94daaa502b998eb4d5403a69b90e5ca37e282e3faa03d7f890731ad425cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biological activity</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - pathology</topic><topic>Cell adhesion & migration</topic><topic>Cell cycle</topic><topic>Cell division</topic><topic>Cell migration</topic><topic>Chemotherapy</topic><topic>Datasets</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene regulation</topic><topic>Gene Regulatory Networks</topic><topic>Gene sequencing</topic><topic>Genomes</topic><topic>Glioblastoma</topic><topic>Glioblastoma - genetics</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - pathology</topic><topic>Glioma</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Multivariate analysis</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Regression Analysis</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Long Noncoding - genetics</topic><topic>Software</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Training</topic><topic>Transcription</topic><topic>Tumors</topic><topic>Up-Regulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Jizong</creatorcontrib><creatorcontrib>Lin, Fa</creatorcontrib><creatorcontrib>Zeng, Chaofan</creatorcontrib><creatorcontrib>Ge, Peicong</creatorcontrib><creatorcontrib>Zhang, Qian</creatorcontrib><creatorcontrib>Li, Junsheng</creatorcontrib><creatorcontrib>Wang, Wen</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Jizong</au><au>Lin, Fa</au><au>Zeng, Chaofan</au><au>Ge, Peicong</au><au>Zhang, Qian</au><au>Li, Junsheng</au><au>Wang, Wen</au><au>Tu, Wen-Jun</au><au>Wen-Jun Tu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>0278-0240</issn><eissn>1875-8630</eissn><abstract>Objective. The overall survival of patients with recurrent glioblastoma (rGBM) is quite different, so clinical outcome prediction is necessary to guide personalized clinical treatment for patients with rGBM. The expression level of lncRNA FAM225B was analyzed to determine its prognostic value in rGBMs. Methods. We collected 109 samples of Chinese Glioma Genome Atlas (CGGA) RNA sequencing dataset and divided into training set and validation set. Then, we analyzed the expression of FAM225B, clinical characteristics, and overall survival (OS) information. Kaplan-Meier survival analysis was used to estimate the OS distributions. The prognostic value of FAM225B in rGBMs was tested by univariate and multivariate Cox regression analyses. Moreover, we analyzed the biological processes and signaling pathways of FAM225B. Results. We found that FAM225B was upregulated in rGBMs (P=0.0009). The expression of FAM225B increased with the grades of gliomas (P<0.0001). The OS of rGBMs in the low-expression group was significantly longer than that in the high-expression group (P=0.0041). Similar result was found in the training set (P=0.0340) and verified in the validation set (P=0.0292). In multivariate Cox regression analysis, FAM225B was identified to be an independent prognostic factor for rGBMs (P=0.003). Biological process and KEGG pathway analyses implied FAM225B mainly played a functional role on transcription, regulation of transcription, cell migration, focal adhesion, etc. Conclusions. FAM225B is expected to be as a new prognostic biomarker for the identification of rGBM patients with poor outcome. And our study provided a potential therapeutic target for rGBMs.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>33299501</pmid><doi>10.1155/2020/8888085</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-7304-0255</orcidid><orcidid>https://orcid.org/0000-0002-6735-460X</orcidid><orcidid>https://orcid.org/0000-0001-5099-9834</orcidid><orcidid>https://orcid.org/0000-0002-4047-0256</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0240 |
| ispartof | Disease markers, 2020, Vol.2020 (2020), p.1-7 |
| issn | 0278-0240 1875-8630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7704151 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Biological activity Biomarkers Biomarkers, Tumor - genetics Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - pathology Cell adhesion & migration Cell cycle Cell division Cell migration Chemotherapy Datasets Female Gene Expression Regulation, Neoplastic Gene regulation Gene Regulatory Networks Gene sequencing Genomes Glioblastoma Glioblastoma - genetics Glioblastoma - mortality Glioblastoma - pathology Glioma Humans Male Medical prognosis Multivariate analysis Neoplasm Grading Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Patients Prognosis Radiation therapy Regression Analysis Ribonucleic acid RNA RNA, Long Noncoding - genetics Software Survival Survival Analysis Training Transcription Tumors Up-Regulation |
| title | FAM225B Is a Prognostic lncRNA for Patients with Recurrent Glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T15%3A04%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FAM225B%20Is%20a%20Prognostic%20lncRNA%20for%20Patients%20with%20Recurrent%20Glioblastoma&rft.jtitle=Disease%20markers&rft.au=Zhao,%20Jizong&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2020/8888085&rft_dat=%3Cproquest_pubme%3E2467505207%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2467505207&rft_id=info:pmid/33299501&rfr_iscdi=true |